#USA #Clinical Trials #Cancer Care #Duarte #AccessHope

AccessHope Achieves Significant Growth in Cancer Care

AccessHope, LLC, a pioneering entity in the field of cancer expertise, recently announced that it has reached a remarkable milestone—surpassing 10 million members. This achievement comes in tandem with ongoing efforts to enhance cancer care access across the nation. The organization's commitment to ensuring equitable access to evidence-based cancer treatment is underscored by its extensive track record, having completed over 20,000 cancer case reviews to date.

Founded with the mission of connecting cancer patients with world-class oncological resources, AccessHope has expanded its network to include over 340 subspecialty oncologists, significantly bolstering its capacity to serve patients. Over the past year, the organization has witnessed a staggering growth rate of over 30% in the number of organizations that leverage its innovative solutions. The implications of this expansion are profound, as AccessHope strives to provide comprehensive support to individuals battling cancer nationwide.

Bridging Gaps in Cancer Care

The core objective of AccessHope is to ensure that every cancer patient receives the highest standard of care, regardless of their geographical location. Utilizing cutting-edge technology, AccessHope can identify viable cases and seamlessly connect patients with subspecialist expertise at National Cancer Institute-designated Comprehensive Cancer Centers (NCI-CCCs) for meticulous case reviews, second opinions, and access to clinical trials.

Such a strategy has proven successful; in 2025, upward of 90% of the reviews conducted by AccessHope recommended at least one adjustment in a patient’s care plan. These adjustments have contributed to more effective cancer management and improved survival rates. Additionally, AccessHope was able to identify relevant clinical trials for over 25% of the reviewed cases, thereby facilitating patient access to pioneering therapies.

Innovations and New Services

In 2025, AccessHope introduced a novel clinical trials service aimed specifically at aiding oncologists and their patients in identifying prospective studies for trial enrollment. Despite the fact that around 20% of cancer patients may qualify for a clinical trial, a mere 4% tend to enroll. This initiative is focused on diminishing longstanding barriers that have historically impeded participation in clinical trials, ultimately expanding access to groundbreaking treatment options that enhance patient outcomes.

AccessHope has also released peer-reviewed research demonstrating that remote expert oncology reviews can lead to significant treatment modifications, especially for those from socioeconomically disadvantaged backgrounds or underserved communities. Among a sample of 5,000 cases analyzed, it was found that expert guidance resulted in treatment alterations for 52% of the patients, with those from lower socioeconomic areas being 25% more likely to experience such changes.

A Look Ahead

As the organization moves into 2026, CEO Brad Kreick emphasized the critical importance of ensuring that every cancer patient has access to the necessary expert guidance during such a challenging phase of life. He reiterated that the growing number of members and persistent innovations illustrate AccessHope's core mission: enhancing access to evidence-based cancer care for all individuals, ensuring they receive the right treatment at the right time, irrespective of their residential area.

In conclusion, AccessHope's journey illustrates the power of technological integration and expert collaboration in the ever-evolving landscape of oncology. With a growing network and enhanced service offerings, AccessHope is not only redefining cancer care access but also setting the blueprint for future advancements in treating this complex disease. By focusing on equitable care, AccessHope is transforming lives, one patient at a time.